Summary of Study ST001408
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000964. The data can be accessed directly via it's Project DOI: 10.21228/M83406 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001408 |
| Study Title | Metabolomic profiling of baseline plasmas from a longitudinal prospective cohort of 491 active surveillance (AS) participants |
| Study Type | Biomarker study |
| Study Summary | Untargeted metabolomics analyses were performed on clinically matched baseline plasma samples (n = 16 per group) prospectively collected from patients with clinically low-risk early stage prostate cancer undergoing AS who exhibited early disease progression (DP) (defined as upgrading of Gleason score (GS) and/or increased tumor volume on surveillance biopsy within 18 months after start of AS) or indolent disease (no progression for five or more years after start of AS) as well as 459 baseline plasma samples prospectively collected from patients with early-stage prostate cancer undergoing AS. |
| Institute | University of Texas MD Anderson Cancer Center |
| Department | Department of Clinical Cancer Prevention |
| Last Name | Vykoukal |
| First Name | Jody |
| Address | 6767 Bertner Ave, Houston, TX 77030 |
| jvykouka@mdanderson.org | |
| Phone | 713-834-6095 |
| Submit Date | 2020-05-19 |
| Raw Data Available | Yes |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-07-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO001477 |
| Collection Summary: | Patients in this prospective clinical cohort included men diagnosed with localized prostate cancer and enrolled on an AS trial protocol between February 2006 and February 2014 (n=825). Of these, 616 patients had at least 1 year follow-up and 491 patients had baseline plasma samples, enabling inclusion in the study. The surveillance protocol was conducted by a multidisciplinary team of urologists, radiation oncologists and medical oncologists, was approved by the Institutional Review Board, and is registered on clinicaltrials.gov (NCT00490763). EDTA was used in all plasma collections and all specimens underwent a similar number of freeze/thaw cycles prior to obtaining metabolomics data. Sample ages varied, as the study began accrual in 2006 and continued over a ten year time period. Plasma was not obtained from fasted individuals. |
| Sample Type: | Blood (plasma) |
